2BBBullish & Bearish
Corcept Therapeutics Incorporated (CORT) trades on NASDAQ. It operates in the Health Care sector, Biotechnology industry. Its current 2BB score is 37 out of 100.
Corcept Therapeutics Inc. is a pharmaceutical company engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic, psychiatric and oncologic disorders. Corcept has focused on the adverse effects of excess cortisol, studying new compounds that may mitigate those effects. Its executive team is headed by CEO, president and director Joseph K. Belanoff, MD.
Corcept Therapeutics Incorporated’s current 2BB score is 37 out of 100, built from the signal categories below.
| Signal | Score | Reading |
|---|---|---|
| Activity | 12 | Very Low |
| Momentum | 48 | Stable |
| Financial strength | 61 | Strong |
| Quality | 100 | Very Strong |
| Risk | 0 | Very Low |
| Headquarters | Menlo Park, California, United States |
| Founded | May 13, 1998 |
| Employees | 730 |
| P/E ratio | 254.60 |
| 52-week range | $28.66 – $91.00 |
| Report date | EPS actual | EPS estimate | Revenue actual | Revenue estimate |
|---|---|---|---|---|
| 2026-11-02 | — | 0.6528 | — | $343.22M |
| 2026-07-29 | — | 0.0051 | — | $224.39M |
| 2026-05-04 | — | -0.0184 | — | $196.36M |
| 2026-02-24 | — | 0.306 | — | $260.03M |